Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Limited (D. Del. 2019)

✉ Email this page to a colleague

Docket	⤷ Try a Trial	Date Filed	2019-12-19
Court	District Court, D. Delaware	Date Terminated	2022-06-01
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Patents	7,737,142; 7,943,621; RE47,350
Attorneys	Christopher B. Ferenc
Firms	Kratz & Barry LLP
Link to Docket	External link to docket

The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .

Subscribe to access the full database, or Try a Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2019-12-19	1	Complaint	United States Patent Nos. 7,737,142 (“the ’142 Patent”) and 7,943,621 (“the ’621 Patent”) (collectively…has listed the asserted patents and U.S. Patent No. RE47,350 (“the ’350 Patent”) in the Approved Drug … 1. This action for patent infringement, brought pursuant to the patent laws of the United States…28. This civil action for patent infringement arises under the patent laws of the United States, including… copy of the ’142 Patent is attached as Exhibit A. 61. The ’621 Patent, titled “Salts of	External link to document
2021-06-02	104	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE47,350 E . (Dorsney, Kenneth… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-08-25	140	Stipulation to EXTEND Time	asserted patents, including U.S. Patent Nos. 7,737,142 (the '142 Patent) and 7,943,621 (the '621 Patent) and…Scheduling Order, for all asserted patents, including the '142 and '621 Patents to September 15, 2021 and September… 2019 1 June 2022 1:19-cv-02317 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document